Primary Outcome Results from the Second Study
The second study 1 found that PROMs-guided postoperative care resulted in a mean difference of 5.5 points (95% credibility interval: 2.3 to 9.2) higher QoR-15 score at postoperative day 35 compared to standard care, though this fell short of the minimal clinically important difference of 6.0 points.
Detailed Primary Outcome Analysis
The primary endpoint in this 2026 randomized controlled trial was the change in QoR-15 scores between the preoperative period and postoperative day 35 1. The study specifically measured:
- Absolute difference: 5.5 points improvement in the experimental (PROMs-guided) group
- Statistical certainty: Probability that this difference is greater than zero was >99.9%
- Clinical significance: Only 39.4% probability that the difference exceeded the MCID threshold of 6 points
Key Interpretation
While the intervention showed a statistically significant benefit with near-certainty (Pr(diff > 0) > 0.999), the clinical relevance was limited as the improvement did not reliably exceed the 6-point MCID for the QoR-15 scale 1. This represents a statistically positive but clinically marginal improvement in postoperative recovery quality.
The study used Bayesian analytical methods and assessed QoR-15 at multiple timepoints (POD 1,3,14, and 28) before the primary endpoint measurement at POD 35 1.
Important Context
The study did demonstrate a clinically meaningful secondary benefit: a 97.4% probability of reduced persistent opioid consumption in the PROMs-guided group (12.3%) compared to standard care (21.2%) 1, which may represent the more clinically relevant outcome from this intervention.